Lu Alleruzzo, Co-Founder & CEO, at Immunophotonics, Inc. will be attending the RESI Boston 2022 Partnering Platform, September 21st & 22nd in Boston at the Westin Copley Place.
Category: Latest News
SACHS Associates 22nd Annual Biotech in Europe Forum
Dr. Theresa Visarius, Immunophotonics Vice President Business Development and Managing Director of the Swiss subsidiary IPS Biopharma AG will be at the SACHS Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment on Wednesday and Thursday, September 21st & 22nd.
Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Conference
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. attended the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Conference on September 10 – 14, 2022 in Barcelona, Spain.
European Society of Medical Oncology (ESMO) Congress
Lu Alleruzzo, Co-Founder & CEO at Immunophotonics, Inc. attended the European Society of Medical Oncology (ESMO) Congress in Paris, France on September 9 – 13, 2022.
Immunophotonics Announces Appointment of New Chief Medical Officer and Chief Scientific Officer
Immunophotonics, Inc. is thrilled to announce the addition of Dr. Edwina Baskin-Bey in the role of Chief Medical Office (CMO) and Dr. David Anderson in the role of Chief Scientific Officer (CSO). Dr. Baskin-Bey’s vast experience in leading global clinical development and regulatory strategy across multiple therapeutic areas will strengthen the clinical development program as...
Tomas Hode, Wei R. Chen, Siu Kit “Samuel” Lam T Cell Paper Publication
Immunophotonics would like to congratulate Ashley Hoover and Kaili Liu lead authors from the University of Oklahoma and to the co-authors Tomas Hode, Wei Chen, and Sui Kit “Samuel” Lam on the T-Cell Paper publication in Clinical and Translational Medicine July 2022 issue. Check out this pivotal publication on how immunological remodeling of T-cells can...
Swiss MedTech Day June 14, 2022
Dr. Theresa Visarius, VP of Business Development at Immunophotonics, Inc. will be attending 2022 Swiss MedTech Day on Tuesday, June 14, 2022 in Kursaal Bern Switzerland.
Society of Interventional Radiology Annual Scientific Meeting (SIR), June 11-16, 2022
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the Society of Interventional Radiology Annual Scientific Meeting (SIR) in Boston, MA June 11 – 16, 2022.
Immunophotonics Announces First Patient Dosed in Phase 2a Clinical Trial of IP-001 in advanced solid tumor indications
Immunophotonics announced that the first patient has been dosed in the phase 2a portion of its Swiss clinical trial for treatment of multiple selected cancer indications. This multicenter clinical trial is designed to evaluate the immunologically mediated anticancer effects of intratumorally injecting the company’s lead asset, IP-001, following thermal ablation in patients with advanced solid...
Immunophotonics HEC-TV Interview
Immunophotonics was interviewed by HEC-TV, St. Louis on our lead asset IP-001. Immunophotonics would not be where they are today if it weren’t for the entire team, many of whom are featured in this segment. Great Job Abby Delawder, Chun Fung (Johnny) Wong, Siu Kit (Samuel) Lam, Lu Alleruzzo, Tomas Hode. To View Click Here